Return-path: <>
Envelope-to: lbaez@edenetsa.com
Delivery-date: Mon, 03 Nov 2014 23:20:34 -0400
Received: from [79.41.90.38] (port=2524 helo=79.41.90.38)
	by host8.dnns.net with smtp (Exim 4.82)
	id 1XlUfZ-0005rm-D6
	for lbaez@edenetsa.com; Mon, 03 Nov 2014 23:20:33 -0400
Received: from unknown (HELO localhost) (l_rand@stocker-verlag.com@222.221.56.110)
	by 79.41.90.38 with ESMTPA; Tue, 4 Nov 2014 04:23:59 +0100
From: l_rand@stocker-verlag.com
To: lbaez@edenetsa.com
Subject: This company is about to become a cash cow
Date: Tue, 4 Nov 2014 04:14:00 +0100

"Oncolytics Biotech" Biotechnology Company is focused on the 
development of oncolytic viruses for their further use in the 
treatment of various forms of cancer. The top company's drug - 
"REOLYSIN" - is currently in the final stage of clinical testings 
against cancer of head and neck. The product's action is based on the 
reovirus (Respiratory Enteric Orphan virus) ability to determine and 
"infect" the cells with the mutated RAS gene. After mutation the gene 
transforms a normal cell into a cancer one. "REOLYSIN", made by the 
Canadian company "Oncolytics Biotech Inc", not only detects the cancer 
cells with the mutated gene, but is also cytocidal. Provided that 2/3 
of tumors have cells with the mutated RAS gene, there is a hope that 
complicated and even propagating tumors might be cured without 
radiation and chemotherapy.

According to recent data, the application of the reovirus medicine in 
conjunction with chemotherapeutic treatment enlarges the ratio of 
fortunate result for the treatment of the head and neck cancer up to 
74%.

"Oncolytics Biotech Inc (ONCY)" Company's shares have been presented 
on NASDAQ since 2001, Market Cap 72.36M, rated by Zacks "Strong Buy". 
At the end of trading on 03/11/2014, the stock price was $0.88, which 
is a favorable entry point for investing in new advanced technologies.

Let us recall that "Oncolytics Biotech Inc" Company was established in 
Calgary in 1998 in response to developments made on the oncolytic 
potential of reovirus at the University of Calgary during the 1990s. 
In 1999-2000 the company transitioned from private to public 
ownership. 

The firm was granted its first Canadian patent in August 2000, and 
currently owns more than 200 patents worldwide, including 38 U.S. and 
11 Canadian patents.